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ABSTRACT 
 
Cholera is an important diarrheal disease in developing countries. WHO estimates that 
cholera caused 111,575 cases with 1,894 deaths in the year 2003 worldwide. To 
overcome that problem, a number of cholera vaccine candidates have been developed by 
mutation or deletion of various genes such as thyA and gln. However, these 
auxotrophic strains were leaky and able to grow in the small intestine of experimental 
animal’s in-vivo. Objective of the study was to develop an auxotrophic vaccine strains 
by mutating the housekeeping gene, hemA gene in V. cholerae. The hemA gene codes 
for glutamyl tRNA reductase. The hemA gene plays a major rate-limiting step in delta 
aminolevulinic acid (ALA). The hemA gene was PCR amplified from V. cholerae O1 El 
Tor and cloned into pARO180 vector at EcoRI site. To mutate the hemA gene, a 
kanamycin cassette was inserted at the BstXI site. hemA-kan was first subcloned into 
conjugative suicide vector pWM91 which was then, conjugatively transferred into V. 
cholerae O1 El Tor and the mutant obtained was designated as VCUSM3. In order to 
remove the kanamycin cassette, the hemA gene was inserted with GFP gene flanking 
with SmiI site and subcloned onto pWM91. GFP gene was then excised and left a +1 
frame shift mutation in hemA gene (hemA*/M). hemA*/M was conjugatively 
transferred to VCUSM3 and the mutant obtained was designated as VCUSM4. ALA 
auxotrophy of VCUSM3 and VCUSM4 were confirmed by their growth on ALA 
supplemented medium. The hemA mutants were confirmed by PCR using hemA 
specific primers and by DNA sequencing. Thus in this study ALA auxotrophs of V. 
cholerae O1 El Tor were created by mutating the hemA gene. 
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PEMBANGUNAN AUXOTROPIK DELTA ASID AMINO LEVULINIK  
PADA VIBRIO CHOLERAE O1 EL TOR OGAWA 
 
ABSTRAK 
 
kolera merupakan penyakit cirit-birit yang penting di negara-negara membangun. Pada 
tahun 2003, WHO menganggarkan sebanyak 111,575 kes kolera dengan 1,894 kematian 
berlaku di seluruh dunia. Untuk mengatasi masalah ini, beberapa vaksin kolera telah 
dicipta melalui memutasikan atau mendelesikan berbagai-bagai jenis gen seperti thyA 
dan gln. Walaubagaimanapun, strain auxotropik ini didapati berupaya hidup di dalam 
usus kecil haiwan kajian di makmal. Oleh itu, kajian ini bertujuan untuk 
membangunkan vaksin auxotropik melalui mutasi gen “housekeeping” pada V. cholerae 
iaitu gen hemA. Gen hemA mengkodkan untuk enzim glutamyl tRNA reductase. Ia 
berperanan sebagai penentu kadar di dalam pembentukan ALA. Gen hemA di PCR 
amplifikasikan daripada V. cholerae O1 El Tor dan diklonkan kedalam vector 
pARO180 pada kedudukan EcoRI. Kaset kanamycin dimasukkan pada kedudukan 
BstXI untuk memutasikan gen hemA. hemA-kan disubklonkan kedalam vector 
pWM91. Seterusnya, ia dipindahkan secara konjugatif kepada V. cholerae O1 El Tor, 
dan menghasilkan VCUSM3. Kaset kanamycin disingkirkan melalui pengantian dengan 
GFP yang mempunyai SmiI pada kedua-dua hujungnya dan disubklonkan ke dalam 
vector pWM91. “Frame shift” +1 terhasil apabila gfp disingkirkan. Mutan VCUSM4 
dihasilkan apabila hemA*/M dipindahkan secara konjugatif kepada VCUSM3. ALA 
auxotropik VCUSM3 dan VCUSM4 disahkan melalui pertumbuhan pada medium agar 
yang dibekalkan dengan ALA. PCR menggunakan primer spesifik terhadap hemA dan 
 19
analisis penjujukan DNA dilakukan untuk mengesahkan mutan hemA. Kajian ini telah 
berjaya, menghasilkan V. cholerae O1 El Tor ALA auxotropik melalui kaedah mutasi 
pada gen hemA.  
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Historical Background  
 
 
There have been seven pandemics of cholera in recorded history. Even though the 
etiological agents of the first four pandemics are not known since they occurred in the 
time before such agents could be recognized, the last three pandemics are known to be 
due to Vibrio cholera serogroup O1. The modern history of cholera began in 1817, 
when cholera spread out of India described as the first of seven pandemics (Pollitzer, 
1959). The disease poured out of Bengal, extending far beyond its normal habitat, and 
attacked large populations in many countries. The first pandemic recorded from 1817 to 
1823, reaching China and Japan to the East; to the West, it spread to the shores of the 
Mediterranean and Zanzibar on the east coast of Africa (Pollitzer, 1959; Snow, 1855). 
The pandemic ended when the disease completely disappeared from any region outside 
India. In early 1830, the second pandemic of cholera reached the British Isles, Russia, 
Poland, Austria, Ireland and France. Cholera was first reintroduced into China in 1840 
by British troops transferred from India.  
 
The third pandemic was stated by Pollitzer to have begun in 1852, extending to Persia 
and Mesopotamia and to Europe. Whereas, the fourth pandemic occurred in 1873 and 
the outbreak was stopped in 1875. In 1881 the fifth pandemic extensively affected South 
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America; it caused large epidemics in many countries and was characterized by high 
mortality in Argentina, Chile and Peru (Laval, 1989). During the fifth pandemic, Robert 
Koch successfully isolated the causative organism of cholera, referred to as “comma 
bacilli” (Koch, 1884), from rice water stools of patients in Egypt in 1883 and in India in 
1884. The sixth pandemic began in 1899; disease persisted in Eastern Europe until 
1923. According to John et al., (2000), cholera has been epidemic in Southern Asia for 
at least 1000 years, but also spread worldwide to cause seven pandemics since 1817.  
 
The seventh pandemic is the most extensive of the pandemics in geographic spread and 
in duration. The pandemic, which began in 1961 on the island of Sulawesi in Indonesia, 
spread to other islands, including Java, Sarawak, and Borneo and then to the 
Philippines, Sabah and Taiwan, thereby affecting the entire Southeast Asian archipelago 
by the end of 1962 (Kamal, 1974). In 1992, epidemic cholera was reported in Madras 
and other places in India and in Southern Bangladesh (Cholera Working Group, 1993; 
Ramamurthy et al., 1993). Although the clinical syndrome was typical of cholera, the 
causative agent was a V. cholerae non-O1 strain, which was later serogrouped as O139 
and given the synonym name “Bengal” (Shimada et al., 1993). This new serogroup may 
represent the etiologic agent of a new eight pandemic of cholera.  
 
The word “Cholera” has been used for over 2,500 years to describe any diarrhea and 
vomiting, not just that caused by bacteria. There is considerable debate over the origin 
of the term cholera and which ancient cultures the disease touched. According to the 
works of Hippocrates, it was believed that the word has been derived from the Greek 
word “chole” (bile) and “rein” (flow), which means, “flow of bile”. Whereas another 
possible derivation is from the Hebrew, meaning “bad disease” (Kaper et al., 1995). 
Alexander Trallianus, however said that the word had come from “cholades” which 
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means intestine, as the evacuations were often serous and not bilious (Diman Barua and 
Greenough, 1992). 
 
1.2 Vibrio cholerae  
 
Members of the genus Vibrio are Gram negative, nonsporing, and straight or curved 
rods measuring about 0.5 to 0.8 m in diameter and 1.4 to 2.1 m in length (Kay et al., 
1994). Stephen (2001) described V. cholerae as a “comma - shaped” bacterium. Only 
aerobic or facultatively anaerobic rods with fermentative metabolism have been retained 
in this genus. Most species are oxidase positive. A biochemical test characteristic 
between Vibrio cholerae and Enterobacteriaceae was showed in Table 1.1.  
 
The genus Vibrio contains more than 50 species, including three species that are 
frequently isolated from human clinical samples; V. cholerae, V. parahaemolyticus and 
V. vulnificus, and four other species that are isolated more rarely; V. alginolyticus, V. 
fluvialis, V. hollisae and V. mimicus. About one third of these species in the genus 
Vibrio are pathogenic for humans. The most pathogenic Vibrio. spp are motile by 
monotrichous or loptrichous flagella which are surrounded by the sheath in liquid media 
(Kenneth, 2000). On solid media they may synthesize numerous lateral flagella, which 
are not sheathed. Vibrio cholerae grow in alkaline conditions up to a maximum of pH 
10 but sensitive to acidic conditions, where most are dying in the stomach, where the 
pH is 6 or below (Pollitzer, 1959).  
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Table 1.1 Differential characteristics of selected members of the Vibrionaceae and 
Enterobacteriaceae (Kay et al., 1994). 
 
 
       Reactiona 
Test          Vibrio     Vibrio     Halophilic  Aeromonas   Aeromonas    Plesiomonas    Enterobacteriaceae 
       cholerae mimicus  vibrios       hydrophila    veronii           shigelloides 
 
KIA      K/A         K/A         V  V    K/AG                 K/A   V 
TSI      A/A         K/A         V  V    A/AG    K/A   V 
String        +           +            +b                     
Oxidase        +           +            +  +        +       +    
Gas from                             c  +        +          V 
glucose 
Sucrose        +                       V  V        +          V 
Lysine          +           +            V  V        +       +   V 
Arginine                             V  +               +   V 
Ornithine     +           +            V          +       +   V 
VP      V                       V  V        +          V 
Growth in    +           +              +        +       +   + 
0% NaCld 
Growth in    +           +            +  +        +       +   + 
1% NaCld 
a+, positive; a,  negative;V, variable reaction;K, alkaline; A, acid; G, gas produced. 
b V, parahaemolyticus; V. cincinnatiensis, and V. damsela show variable reactions. 
cV. furnissii and V. damsela are variable. 
dNutrient broth base. 
 
 24
Vibrios are one of the most common organisms in surface waters of the world. They 
occur in both marine and freshwater habitats and in association with aquatic animals 
(Charles et al., 1994). Studies of the organism in the environment have found that vibrio 
is able to survive for extended periods in aquatic and estuarine areas. The survival of V. 
cholerae in the environment was thought to be short which less than one week is in 
seawater (Chavalier et al., 1980). However, since vibrios are typically marine organisms 
most species require 2–3% NaCl or a seawater base for optimal growth. Most vibrios 
have relatively simple growth factor requirements and will grow in synthetic media with 
glucose as a sole source of carbon and energy. Vibrios vary in their nutritional 
versatility, but some species will grow on more than 150 different organic compounds 
as carbon and energy sources, occupying the same level of metabolic versatility as 
Pseudomonas. 
 
Most pathogenic vibrio species are found as part of the autochthonous microbial 
community in brackish and marine environments in temperate or tropical regions 
throughout the world. Vibrio cholerae and V. mimicus have been isolated from fresh 
water lakes and rivers and from birds and herbivores in areas geographically removed 
from marine and coastal water (Bockemuchl et al., 1986; Ogg et al., 1989; Rhobes et 
al., 1985 and 1986). The incidence and density of pathogenic vibrio. spp decrease 
significantly as water temperatures fall below 20C. Vibrio. spp also can be found in the 
water column and surface sediment and are associated with mollusks and crustaceans. 
Vibrio cholerae, Vibrio parahaemolyticus and Vibrio vulnificus are known to be 
pathogens of humans. Both Vibrio cholerae and Vibrio parahaemolyticus produce 
diarrhea, but in ways that are entirely different. V. parahaemolyticus is an invasive 
organism affecting primarily the colon, whereas V. cholerae is non invasive and 
